Neurosterix

Neurosterix is a biopharmaceutical company developing allosteric modulator therapeutics for neurological disorders. Its lead program is an M4 PAM for schizophrenia, leveraging a proprietary high-throughput drug discovery platform acquired from Addex Therapeutics. The company aims to improve efficacy and safety of treatments through this innovative approach.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $63M

Date: 03-Apr-2024

Investors: Perceptive Xontogeny Venture Fund II, Perceptive Life Sciences Fund, Acorn Bioventures

Markets: Biopharmaceutical, Neuroscience, Pharmaceutical, Biotechnology Research, Drug Discovery

HQ: Geneva, Geneva, Switzerland

Founded: 2024

Website: https://www.neurosterix.com/

LinkedIn: https://www.linkedin.com/company/neurosterix

Twitter:

Instagram: